Búcsú a rosiglitazontól: Merre tovább?

Translated title of the contribution: Farewell to rosiglitazone: Where to go?

Research output: Contribution to journalArticle

Abstract

The European Medicines Agency concluded that the marketing authorisation for all rosiglitazone-containing medicines (Avandia, Avandamet, Avaglim) should be suspended across the European Union. The National Health Insurance Fund Administration in Hungary in a circular letter called the attention of GP's to the necessity in getting the medical proposal (of an internist, endocrinologist or diabetologist) for substituting rosiglitazone to arrange a smooth modification of their treatment regimen. The review taking into account updated recommendations of the ADA-EASD and the Hungarian Diabetes Association summarises the potential drugs. The first line therapy of choice has to be starting with insulin. Pioglitazone might also be administered, with all known side effects of the glitazone family, e.g. congestive heart failure and bone fractures. Further alternatives are choosing the newer drugs of the incretin principle: the incretin mimetics (exenatid, liraglutid) and the incretin enhancers (sitagliptin, vildagliptin, saxagliptin). Beside their favourable profile of effect they do not have longterm follow up outcome studies and evidences for cardiovascular safety.

Translated title of the contributionFarewell to rosiglitazone: Where to go?
Original languageHungarian
Pages (from-to)805-811
Number of pages7
JournalLege Artis Medicinae
Volume20
Issue number12
Publication statusPublished - Dec 1 2010

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Farewell to rosiglitazone: Where to go?'. Together they form a unique fingerprint.

  • Cite this